Literature DB >> 25783962

A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness.

G K Chimal-Ramírez, N A Espinoza-Sánchez, E M Fuentes-Pananá1.   

Abstract

In solid tumors, neoplastic cells are surrounded by a specific microenvironment that integrates the extracellular matrix, lymphatic and blood vessels, and mesenchymal and immune cells, which together are known as the tumor microenvironment (TME). The TME governs many of the aggressive features of tumors, such as local invasion and metastasis. Additionally, new evidence indicates that the TME can trigger stem cell-like programs in cancer cells, forming cancer stem cells (CSC). Experimental and clinical studies suggest that CSCs are resistant to current common cancer therapies and are responsible for tumor recurrence. In this review, we will describe the TME by focusing on how matrix metalloproteinases (MMPs) and cyclooxygenase-2 (COX-2) induce stemness and sustain stem cell maintenance. This reprogramming toward a CSC phenotype may be critical in tumor cell responses to chemotherapy and relapse with more aggressive tumor clones. Therefore, therapeutic agents targeting MMPs and COX-2 in the tumor microenvironment may become important drugs to control the establishment of CSCs and in the overall prognosis of the disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25783962     DOI: 10.2174/1871520615666150318100822

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  8 in total

1.  Screening the active compounds of Phellodendri Amurensis cortex for treating prostate cancer by high-throughput chinmedomics.

Authors:  Xian-Na Li; Aihua Zhang; Meijia Wang; Hui Sun; Zhidong Liu; Shi Qiu; Tianlei Zhang; Xijun Wang
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

2.  Evidence of lateral transmission of aggressive features between different types of breast cancer cells.

Authors:  Nancy Adriana Espinoza-Sánchez; Eduardo Vadillo; Juan Carlos Balandrán; Alberto Monroy-García; Rosana Pelayo; Ezequiel M Fuentes-Pananá
Journal:  Int J Oncol       Date:  2017-09-19       Impact factor: 5.650

3.  An NFκB-dependent mechanism of tumor cell plasticity and lateral transmission of aggressive features.

Authors:  Nancy Adriana Espinoza-Sánchez; Jennifer Enciso; Rosana Pelayo; Ezequiel M Fuentes-Pananá
Journal:  Oncotarget       Date:  2018-06-01

4.  Differential impact of classical and non-canonical NF-κB pathway-related gene expression on the survival of breast cancer patients.

Authors:  Nancy Adriana Espinoza-Sánchez; Balázs Győrffy; Ezequiel M Fuentes-Pananá; Martin Götte
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

5.  Claudin-Low Breast Cancer Inflammatory Signatures Support Polarization of M1-Like Macrophages with Protumoral Activity.

Authors:  Mayra Cecilia Suárez-Arriaga; Alfonso Méndez-Tenorio; Vadim Pérez-Koldenkova; Ezequiel M Fuentes-Pananá
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

6.  Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer.

Authors:  Qinghong Guo; Xiaojun Liu; Linzhi Lu; Hao Yuan; Yuping Wang; Zhaofeng Chen; Rui Ji; Yongning Zhou
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

7.  Downregulation of mitochondrial cyclooxygenase-2 inhibits the stemness of nasopharyngeal carcinoma by decreasing the activity of dynamin-related protein 1.

Authors:  Teng-Jian Zhou; Shi-Li Zhang; Cheng-Yong He; Qun-Ying Zhuang; Pei-Yu Han; Sheng-Wei Jiang; Huan Yao; Yi-Jun Huang; Wen-Hua Ling; Yu-Chun Lin; Zhong-Ning Lin
Journal:  Theranostics       Date:  2017-03-23       Impact factor: 11.556

Review 8.  Adverse Health Effects of Betel Quid and the Risk of Oral and Pharyngeal Cancers.

Authors:  Ping-Ho Chen; Qaisar Mahmood; Gian Luigi Mariottini; Tai-An Chiang; Ka-Wo Lee
Journal:  Biomed Res Int       Date:  2017-12-11       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.